Gao Song: In fact, we have always done this

[shapanwwuom]

This not only improves the accuracy of diagnosis, but also significantly shortens the time for report issuance, plays an important role in report interpretation and clinical decision-making, and provides customers with more valuable information and assistance for future decision-making, thereby greatly improving the customer experience.

Of course, we are also committed to improving the medical value of testing through AI, continuously upgrading our internal IT infrastructure, and integrating AI capabilities into new IT systems. Currently, the new LIMS system has been launched, and about half of the subsidiaries have installed the new system. It will be promoted to all subsidiaries this year, and other related systems are also planned to be upgraded in 2025.

At the same time, the company is constantly seeking potential partners for leading AI technologies and applications at home and abroad, actively exploring more application scenarios of AI, and seeking potential opportunities to optimize or innovate traditional practices.

We believe that over time, these systems will help us better control costs, improve quality and efficiency, and drive the company's overall operations to a higher level.

Glodon: In the context of increasing global economic botim data uncertainty, will the company consider enhancing its global competitiveness through international cooperation?

Our major shareholder, Carlyle, has extensive global resources and continues to introduce high-quality potential international partners to us. For example, our cooperation with Guardant Health has been successfully implemented. The significant growth of the company's special inspection business, especially tumor detection business in 2024, is mainly based on the promotion of Guardant Health.

There are many leading technologies in the world today. As long as it is based on the concept of mutual benefit and win-win cooperation, we will continue to maintain an open attitude towards cooperation in the future.

Glodon: Can you share the company’s development plans for next year and the next three to five years?

Gao Song: Based on the second five-year development strategy just mentioned, we hope to first achieve faster growth that exceeds the industry average growth rate, and secondly, we hope that the profit growth rate can exceed the sales growth rate. In addition, given the high operating leverage and significant economies of scale in the ICL industry, our goal in the medium to long term is to seek further breakthroughs and development while consolidating our leading position in the industry.